Table 9.6a
Immunosuppression Use for Induction, 1996 to 2005
Recipients with Liver Transplants

	Year of Transplant									
	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005
Transplants	4,082	4,186	4,516	4,751	4,995	5,190	5,331	5,672	6,167	6,441
With Immunosuppression Info	3,529	3,868	4,199	4,441	4,846	5,027	5,198	5,520	5,970	6,083
Induction Drugs										
ALG	0.2%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Atgam/NRATG/NRATS	3.7%	2.1%	1.2%	0.7%	0.7%	0.4%	0.5%	0.5%	0.4%	0.2%
OKT3	6.7%	4.9%	3.6%	1.4%	0.8%	0.7%	0.3%	0.3%	0.2%	0.8%
Thymoglobulin	0.0%	0.0%	0.1%	0.5%	1.2%	2.4%	4.2%	6.5%	7.4%	7.3%
Zenapax	0.0%	0.0%	2.9%	6.6%	6.6%	5.8%	4.6%	5.6%	4.6%	4.0%
Simulect	0.0%	0.1%	1.4%	4.4%	6.6%	6.2%	7.8%	7.2%	6.4%	7.1%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.7%	1.6%	1.6%
No Induction Drugs Recorded	89.6%	92.9%	91.0%	86.7%	84.5%	84.6%	82.7%	79.5%	79.6%	79.8%

Source: OPTN/SRTR Data as of May 1, 2006.
Notes:
Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.